PortfoliosLab logo
PortfoliosLab logo
Tools
Performance Analysis
Portfolio Analysis
Factor Model
Portfolios
Lazy PortfoliosUser Portfolios
Discussions
Magnum Experiment 23A
Performance
Risk-Adjusted Performance
Dividends
Drawdowns
Volatility
Diversification

Asset Allocation


ADMA 23.44%APP 21.45%CVNA 15.29%ARQT 11.07%MSTR 8.51%WULF 6.39%INOD 5.91%SMR 4.71%SMMT 1.77%LBPH 1.47%EquityEquity
PositionCategory/SectorTarget Weight
ADMA
ADMA Biologics, Inc.
Healthcare
23.44%
APP
AppLovin Corporation
Technology
21.45%
ARQT
Arcutis Biotherapeutics, Inc.
Healthcare
11.07%
CVNA
Carvana Co.
Consumer Cyclical
15.29%
INOD
Innodata Inc.
Technology
5.91%
LBPH
Longboard Pharmaceuticals, Inc.
Healthcare
1.47%
MSTR
MicroStrategy Incorporated
Technology
8.51%
SMMT
Summit Therapeutics Inc.
Healthcare
1.77%
SMR
Nuscale Power Corp
Industrials
4.71%
WULF
TeraWulf Inc.
Financial Services
6.39%

Performance

Performance Chart

The chart shows the growth of an initial investment of $10,000 in Magnum Experiment 23A, comparing it to the performance of the S&P 500 index or another benchmark. All prices have been adjusted for splits and dividends. The portfolio is rebalanced every 3 months.


0.00%20.00%40.00%60.00%80.00%100.00%120.00%AugustSeptemberOctoberNovemberDecember2025
88.97%
5.98%
Magnum Experiment 23A
Benchmark (^GSPC)
Portfolio components

The earliest data available for this chart is Mar 1, 2022, corresponding to the inception date of SMR

Returns By Period


YTD1M6M1Y5Y*10Y*
^GSPC
S&P 500
0.62%-1.93%5.98%23.72%12.67%11.33%
Magnum Experiment 23A5.28%-3.59%88.97%353.82%N/AN/A
ADMA
ADMA Biologics, Inc.
8.22%-3.38%50.77%274.19%32.82%5.81%
APP
AppLovin Corporation
1.66%2.54%301.41%712.24%N/AN/A
ARQT
Arcutis Biotherapeutics, Inc.
9.62%16.12%42.31%268.84%N/AN/A
CVNA
Carvana Co.
-3.13%-16.71%51.62%321.48%17.65%N/A
INOD
Innodata Inc.
-6.98%-3.97%121.98%388.18%100.40%29.73%
LBPH
Longboard Pharmaceuticals, Inc.
0.00%0.00%56.36%164.70%N/AN/A
MSTR
MicroStrategy Incorporated
14.53%-12.09%144.16%486.38%88.07%35.62%
SMMT
Summit Therapeutics Inc.
5.46%4.73%116.82%525.25%67.48%N/A
SMR
Nuscale Power Corp
9.76%-11.11%50.69%677.87%N/AN/A
WULF
TeraWulf Inc.
-2.65%-18.01%16.00%159.91%2.92%-8.58%
*Annualized

Monthly Returns

The table below presents the monthly returns of Magnum Experiment 23A, with color gradation from worst to best to easily spot seasonal factors. Returns are adjusted for dividends.


JanFebMarAprMayJunJulAugSepOctNovDecTotal
202413.59%17.16%22.96%-8.09%40.19%13.36%9.86%24.54%17.50%-0.78%40.33%-13.02%365.45%
20234.46%-0.15%-4.54%2.75%14.49%0.06%16.19%-3.78%-13.39%-8.32%5.68%23.63%35.93%
20220.31%-17.47%-3.09%-10.31%14.95%2.79%-16.16%5.74%5.43%5.26%-16.35%

Expense Ratio

Magnum Experiment 23A has an expense ratio of 0.00%, indicating no management fees are charged. Below you can find the expense ratios of portfolio funds side-by-side and effortlessly compare their relative costs.


The portfolio doesn't hold funds that charge fees

Risk-Adjusted Performance

Risk-Adjusted Performance Rank

With an overall rank of 99, Magnum Experiment 23A is among the top 1% of portfolios on our website when it comes to balancing risk and reward. Below is a breakdown of how it compares using common performance measures.


The Risk-Adjusted Performance Rank of Magnum Experiment 23A is 9999
Overall Rank
The Sharpe Ratio Rank of Magnum Experiment 23A is 100100
Sharpe Ratio Rank
The Sortino Ratio Rank of Magnum Experiment 23A is 9999
Sortino Ratio Rank
The Omega Ratio Rank of Magnum Experiment 23A is 9999
Omega Ratio Rank
The Calmar Ratio Rank of Magnum Experiment 23A is 100100
Calmar Ratio Rank
The Martin Ratio Rank of Magnum Experiment 23A is 100100
Martin Ratio Rank
The risk-adjusted ranks indicate the investment's position relative to the market. A rank closer to 100 signifies top-performing investments, while a rank closer to 0 might suggest underperformance, based on the selected ratio. The values are calculated based on the past 12 months of returns.

Risk-Adjusted Performance Indicators

This table presents a comparison of risk-adjusted performance metrics for positions. Risk-adjusted metrics are performance indicators that assess an investment's returns in relation to its risk, enabling a more accurate comparison of different investment options.


Sharpe ratio
The chart of Sharpe ratio for Magnum Experiment 23A, currently valued at 6.95, compared to the broader market-1.000.001.002.003.004.006.951.92
The chart of Sortino ratio for Magnum Experiment 23A, currently valued at 6.18, compared to the broader market-2.000.002.004.006.182.57
The chart of Omega ratio for Magnum Experiment 23A, currently valued at 1.79, compared to the broader market0.801.001.201.401.601.791.35
The chart of Calmar ratio for Magnum Experiment 23A, currently valued at 18.82, compared to the broader market0.002.004.006.008.0010.0018.822.86
The chart of Martin ratio for Magnum Experiment 23A, currently valued at 58.29, compared to the broader market0.0010.0020.0030.0058.2912.10
Magnum Experiment 23A
^GSPC

Portfolio components
Sharpe ratioSortino ratioOmega ratioCalmar ratioMartin ratio
ADMA
ADMA Biologics, Inc.
4.394.941.6611.6130.96
APP
AppLovin Corporation
9.367.101.9421.0098.34
ARQT
Arcutis Biotherapeutics, Inc.
3.353.611.423.1512.93
CVNA
Carvana Co.
3.914.411.534.2532.76
INOD
Innodata Inc.
2.873.691.506.0814.77
LBPH
Longboard Pharmaceuticals, Inc.
1.652.811.374.048.43
MSTR
MicroStrategy Incorporated
4.093.621.429.7921.08
SMMT
Summit Therapeutics Inc.
1.795.241.699.5620.08
SMR
Nuscale Power Corp
4.953.821.467.5822.57
WULF
TeraWulf Inc.
1.392.391.251.907.26

The current Magnum Experiment 23A Sharpe ratio is 6.95. This value is calculated based on the past 1 year of trading data and takes into account price changes and dividends.

Compared to the broad market, where average Sharpe ratios range from 1.33 to 2.07, this portfolio's current Sharpe ratio is in the top 25%, it signifies superior risk-adjusted performance. This means that for the level of risk undertaken, the portfolio is generating impressive returns compared to most others.

Use the chart below to compare the Sharpe ratio of Magnum Experiment 23A with the selected benchmark, providing insights into the investment's historical performance in terms of risk-adjusted returns. Go to the Sharpe ratio tool for more fine-grained control over the calculation options.


Rolling 12-month Sharpe Ratio2.004.006.008.0010.0012.00AugustSeptemberOctoberNovemberDecember2025
6.95
1.92
Magnum Experiment 23A
Benchmark (^GSPC)
Portfolio components

Dividends

Dividend yield

Magnum Experiment 23A provided a 0.00% dividend yield over the last twelve months.


TTM2024202320222021
Portfolio0.00%0.00%0.00%0.00%2.12%
ADMA
ADMA Biologics, Inc.
0.00%0.00%0.00%0.00%0.00%
APP
AppLovin Corporation
0.00%0.00%0.00%0.00%0.00%
ARQT
Arcutis Biotherapeutics, Inc.
0.00%0.00%0.00%0.00%0.00%
CVNA
Carvana Co.
0.00%0.00%0.00%0.00%0.00%
INOD
Innodata Inc.
0.00%0.00%0.00%0.00%0.00%
LBPH
Longboard Pharmaceuticals, Inc.
0.00%0.00%0.00%0.00%0.00%
MSTR
MicroStrategy Incorporated
0.00%0.00%0.00%0.00%0.00%
SMMT
Summit Therapeutics Inc.
0.00%0.00%0.00%0.00%0.00%
SMR
Nuscale Power Corp
0.00%0.00%0.00%0.00%0.00%
WULF
TeraWulf Inc.
0.00%0.00%0.00%0.00%33.22%

Drawdowns

Drawdowns Chart

The Drawdowns chart displays portfolio losses from any high point along the way. Drawdowns are calculated considering price movements and all distributions paid, if any.


-20.00%-15.00%-10.00%-5.00%0.00%AugustSeptemberOctoberNovemberDecember2025
-12.46%
-2.82%
Magnum Experiment 23A
Benchmark (^GSPC)
Portfolio components

Worst Drawdowns

The table below displays the maximum drawdowns of the Magnum Experiment 23A. A maximum drawdown is a measure of risk, indicating the largest reduction in portfolio value due to a series of losing trades.

The maximum drawdown for the Magnum Experiment 23A was 41.36%, occurring on May 11, 2022. Recovery took 297 trading sessions.

The current Magnum Experiment 23A drawdown is 12.46%.


Depth

Start

To Bottom

Bottom

To Recover

End

Total

-41.36%Apr 5, 202226May 11, 2022297Jul 19, 2023323
-32.77%Aug 15, 202349Oct 23, 202352Jan 8, 2024101
-19%Jul 17, 202416Aug 7, 20242Aug 9, 202418
-16.85%Nov 21, 202427Dec 31, 2024
-14.64%Mar 2, 20224Mar 7, 202215Mar 28, 202219

Volatility

Volatility Chart

The current Magnum Experiment 23A volatility is 15.81%, representing the average percentage change in the investments's value, either up or down over the past month. The chart below shows the rolling one-month volatility.


0.00%5.00%10.00%15.00%20.00%25.00%AugustSeptemberOctoberNovemberDecember2025
15.81%
4.46%
Magnum Experiment 23A
Benchmark (^GSPC)
Portfolio components

Diversification

Asset Correlations Table

The table below displays the correlation coefficients between the individual components of the portfolio, the entire portfolio, and the chosen benchmark.

LBPHSMMTSMRARQTADMAINODWULFAPPCVNAMSTR
LBPH1.000.110.100.110.140.150.120.170.140.16
SMMT0.111.000.090.230.200.190.150.170.170.16
SMR0.100.091.000.230.230.220.260.210.220.25
ARQT0.110.230.231.000.270.210.270.190.230.22
ADMA0.140.200.230.271.000.290.250.320.300.31
INOD0.150.190.220.210.291.000.320.320.310.31
WULF0.120.150.260.270.250.321.000.340.370.50
APP0.170.170.210.190.320.320.341.000.520.47
CVNA0.140.170.220.230.300.310.370.521.000.45
MSTR0.160.160.250.220.310.310.500.470.451.00
The correlation results are calculated based on daily price changes starting from Mar 2, 2022
PortfoliosLab logo
Performance Analysis
Portfolio AnalysisPortfolio PerformanceStock ComparisonSharpe RatioMartin RatioTreynor RatioSortino RatioOmega RatioCalmar RatioSummers Ratio
Community
Discussions


Disclaimer

The information contained herein does not constitute investment advice and made available for educational purposes only. Prices and returns on equities are listed without consideration of fees, commissions, taxes, penalties, or interest payable due to purchasing, holding, or selling.

Copyright © 2025 PortfoliosLab